Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines

By C. Melief, S. H. Burg. Nature Reviews. Cancer, 2008

626 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Exploiting the mutanome for tumor vaccination. (2012, background): “T cells and processing to be presented onMHCmolecules (28).”
Designer vaccine nanodiscs for personalized cancer immunotherapy (2016, neutral): “clinical trials has been disappointing, a phenomenon that has been attributed to inefficient co-delivery of Ag peptides and adjuvants to draining lymph nodes (dLNs), and subsequent immunological tolerance and CTL fratricide 1 .”
From Vaccines to Memory and Back (2010, positive): “In addition, vaccines to fight cancer and autoimmune diseases are now a highly sought after goal and represent an exciting new area of vaccine research and development (Larche and Wraith, 2005; Lollini et al., 2006; Melief and van der Burg, 2008).”
Coordinate linkage of HIV evolution reveals regions of immunological vulnerability (2011, background): “Discussion Immunogens designed in this way to include only the multidimensionally constrained regions of the HIV proteome, which also contain epitopes presented by diverse HLAs in a population, are candidates for peptide vaccines using synthetic vectors (26), or by linking each segment together, the”